{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"PXD101"},{"type":"CodeName","name":"PXD 101"},{"type":"CASRegistryName","name":"414864-00-9"},{"type":"USBrandName","name":"Beleodaq"}],"definition":{"html":"A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.","text":"A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/belinostat","text":"Belinostat"},"nciConceptId":"C48812","nciConceptName":"Belinostat","termId":454583,"name":"belinostat","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"belinostat"}],"links":null}